Lymphoma section

Featured Lymphoma Content

Recent Advances in Management of Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the clinical treatment options for patients with relapsed Hodgkin lymphoma and anaplastic large cell lymphoma.

Lymphoma News and Features

Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin

Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin

Study reports that patients with classic relapsed/refractory Hodgkin lymphoma who received nivolumab after ASCT experienced high rates of response regardless of previous history with brentuximab vedotin.

Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape

Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape

[Cancer Management and Research] This research summarizes the role of rituximab across the spectrum of FL treatment and the evolving therapeutic landscape with the emergence of novel agents currently in clinical development.

Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors

Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors

Hodgkin lymphoma survivors are at higher risk of second cancers, and that risk is even higher in those with a first-degree relative with cancer.

Treatment Outcomes Were Unchanged by Brentuximab Vedotin (BV)-induced Peripheral Neuropathy

Treatment Outcomes Were Unchanged by Brentuximab Vedotin (BV)-induced Peripheral Neuropathy

Patients who were surveyed reported that the benefits of treatment with BV outweighed its risks.

Pembrolizumab Active in Refractory NK/T-cell Lymphoma

Pembrolizumab Active in Refractory NK/T-cell Lymphoma

PD-1 blockade with pembrolizumab was active and induced durable responses in patients with natural killer (NK)/T-cell lymphoma failing L-asparaginase.

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma

[OncoTargets and Therapy] This research examines the efficacy and safety of recombinant human endostatin in combination with CHOP regimen (ECHOP) for patients with peripheral T cell lymphoma.

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

Researchers sought to compare the efficacy of O-DHAP with R-DHAP as salvage treatment, followed by autologous hematopoietic cell transplantation.

Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma

Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma

The patient's history and current blood work results indicated a dangerously high potassium level. But a meticulously handled redraw proved it false.

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.

Severe Fatigue Associated With Unemployment in Hodgkin Lymphoma Survivors

Severe Fatigue Associated With Unemployment in Hodgkin Lymphoma Survivors

Severe fatigue is associated with unemployment and financial problems in survivors of Hodgkin lymphoma, highlighting the need for clinicians to address fatigue in these patients.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs